Beactica Therapeutics appoints Jarl Ulf Jungnelius M.D. to its Board of Directors as it advances towards clinical-stage activities
Reading Time: 2 minutes STOCKHOLM, June 19, 2023 /PRNewswire/ — Beactica Therapeutics AB, the Swedish precision oncology company, today announced the appointment of Jarl Ulf Jungnelius M.D. to its Board of Directors. The appointment marks another step in Beactica’s strategic plan to become a clinical-stage company. Jarl Ulf Jungnelius M.D. is a licensed medical practitioner and a board-certified oncologist […]
IDTechEx Asks if Liquid Cooling Will Dominate Thermal Management for Data Centers
Reading Time: 4 minutes BOSTON, June 19, 2023 /PRNewswire/ — Over the past 16 years, the thermal design power (TDP) of GPUs has quadrupled. With the increasing demand for AI, cloud computing, and crypto mining, IDTechEx expects the power consumption of server boards and data centers to continue rising. With life starting to return to normal after the end […]
An Integration of Traditional Chinese Medicine and Modern Medicine Realized by Dongzhimen Hospital of Beijing University of Chinese Medicine
Reading Time: 2 minutes BEIJING, June 19, 2023 /PRNewswire/ — A news report by haiwainet.cn: Beijing College of Traditional Chinese Medicine (now Beijing University of Traditional Chinese Medicine) and Dongzhimen Hospital, one of its affiliates, cooperated with The Staudinger Company Group in establishing the TCM-Klinik Bad Kötzting, the first licensed TCM hospital in Germany. In terms of patient diagnosis […]
HxGN EAM Python Framework now available from Hexagon
Reading Time: 3 minutes Hexagon’s Asset Lifecycle Intelligence division has announced the immediate availability of HxGN EAM Python Framework, a new module that features functionality across the entire asset lifecycle for full-scale Python scripting. Python is the world’s fastest-growing programming language and considered the standard programming language for creating machine learning and data science models and applications. Python’s versatility […]
Outsight partners with Indra to accelerate the deployment of 3D LiDAR solutions in smart transport infrastructures
Reading Time: 2 minutes Indra has signed a strategic agreement with the startup Outsight to accelerate the use of artificial vision based on 3D LiDAR in its solutions for the Mobility business, to deploy innovative applications in intelligent transport infrastructures, such as airports, train or bus stations, ports or logistics centres, for both operational and commercial purposes and to […]
Graphene Market size to grow by USD 773.01 million from 2022 to 2027: Growing use of graphene in the construction industry to boost the market growth
Reading Time: 14 minutes NEW YORK, June 19, 2023 /PRNewswire/ — The global graphene market size is estimated to increase by USD 773.01 million from 2022 to 2027. The market’s growth momentum will progress at a CAGR of 34.07% during the forecast period. The growing use of graphene in the construction industry is the key graphene market driver boosting market […]
CORNEX muestra los últimos productos de energÃas renovables en The Smarter E Europe 2023
Reading Time: 2 minutes MUNICH, 19 de junio de 2023 /PRNewswire/ — CORNEX New Energy Co., Ltd. (“CORNEX”), una empresa global de nuevas energÃas comprometida con la innovación de la tecnologÃa de baterÃas de iones de litio, mostró sus productos estrella, entre ellos la célula de baterÃa grande Conergy Ï€314Ah y el armario exterior de refrigeración lÃquida CORNEX 215kWh, […]
First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion
Reading Time: 4 minutes MELBOURNE, Australia, June 19, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)Â today announces that the first patient has been dosed in a Phase II study of the Company’s carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuximab), exploring this potential target across a broad range of cancer indications. The STARBURST study (ClinicalTrials.gov Identifier: […]
First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion
Reading Time: 4 minutes MELBOURNE, Australia, June 18, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)Â today announces that the first patient has been dosed in a Phase II study of the Company’s carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuximab), exploring this potential target across a broad range of cancer indications. The STARBURST study (ClinicalTrials.gov Identifier: […]